Replies to post #73342 on Biotech Values

[DewDiligence]

Re: Copaxone is Cleaning Tysabri’s Clock / genisi

Tysabri's price/patient/year is 2x higher [than Copaxone’s], so I suppose that's a good explanation for the modest annual 3% price increase.

Quite so! This is another reason srsmgja’s argument about price increases is a weak one, IMO.

In terms of patient share, Tysabri remains an also-ran drug in the MS market.